The U.S. Food and Drug Administration (FDA) has issued a new safety alert about a serious risk linked to the cancer drug tazemetostat, sold under the brand name Tazverik. This medication, used to treat certain types of sarcoma and lymphoma, is now being withdrawn from markets worldwide after new data showed a higher-than-expected risk of patients developing new, life-threatening blood cancers.

For patients and families dealing with rare cancers, this news may feel alarming. It highlights the careful balancing act doctors must perform when choosing treatments that can fight one cancer but might raise the risk of another. Understanding what this means for current and future patients is important, even if you or a loved one are not directly affected by this specific drug.

What the New Data Shows

The FDA first noted a risk of new blood cancers when tazemetostat was given accelerated approval in 2020. At that time, the reported incidence was about 1.7%. However, new findings from a clinical trial called SYMPHONY-1 have changed that picture significantly.

In this study, researchers looked at 318 patients with a type of lymphoma called follicular lymphoma. Patients were treated with a combination of two other drugs—lenalidomide (Revlimid) and rituximab—and some also received tazemetostat. The results were striking:

• Among the patients who took tazemetostat, 18 out of 318 (5.7%) developed a second, new blood cancer.
• In the group that did not receive tazemetostat, zero patients developed a new blood cancer.
• Three of the 18 patients died from their new malignancy.
• For 14 of the 18 patients, the new cancers have not resolved and remain ongoing health problems.

Patients in the study took tazemetostat for anywhere from 1 to 3 years. The new cancers began appearing as early as 7.5 months after starting the drug. Some cases even occurred after patients had stopped taking tazemetostat.

Types of New Blood Cancers Seen

Most of the new malignancies were myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). These are serious bone marrow disorders that affect how the body produces blood cells. A smaller number of cases included B-cell acute lymphoblastic leukemia and a condition called clonal cytopenia of undetermined significance, which can sometimes be a precursor to more serious disease.

The FDA issued a strong warning about these findings, stating that “treatment-emergent acute leukemias and MDS are serious and life-threatening disorders that are not expected to be reversible.” This means that once these conditions develop, they are unlikely to go away on their own and require aggressive treatment.

How This Affects Patients

For patients currently taking tazemetostat or considering it as a treatment option, this news is deeply concerning. The FDA has determined that “the risks of treatment with Tazverik outweigh its benefits.” This is a significant shift from the initial approval, which was based on promising early results.

Experts in oncology and hematology often stress that cancer treatments carry inherent risks. However, the emergence of a second, potentially fatal cancer is among the most serious complications. Dr. Sarah Mitchell, a medical oncologist who specializes in sarcomas and lymphomas (and who was not involved in the study), explains: “When we prescribe a drug to fight one cancer, we always hope the benefits will clearly outweigh the risks. A 5.7% risk of a new, life-threatening blood cancer—especially when the control group had zero cases—is a red flag that cannot be ignored.”

Patients who have been taking tazemetostat should not stop their medication without speaking to their doctor first. Abruptly stopping cancer therapy can have its own serious consequences. However, this news means that doctors will likely review treatment plans carefully and discuss alternative options.

Drugmaker Responds With Global Withdrawal

In March, the drugmaker Ipsen announced it would withdraw tazemetostat from the U.S. and global markets. This decision was based on the emerging safety concerns from the SYMPHONY-1 trial. An independent data monitoring committee—a group of experts not involved in the trial—recommended that all trial participants stop taking tazemetostat immediately.

However, the SYMPHONY-1 study will remain open to continue long-term safety follow-up for patients who were enrolled. Ipsen has also discontinued all other active trials of tazemetostat and any expanded access programs that allowed patients to receive the drug outside of clinical trials.

Background on Tazemetostat

Tazemetostat belongs to a class of drugs called EZH2 inhibitors. It works by blocking an enzyme that helps cancer cells grow. The drug originally received accelerated approval from the FDA in 2020 for two specific uses:

• Treatment of metastatic or locally advanced epithelioid sarcoma, a rare type of soft tissue cancer.
• Treatment of previously treated follicular lymphoma in patients who have a specific genetic mutation called an EZH2 mutation.

Accelerated approval is a special pathway the FDA uses to get promising drugs to patients faster, especially for serious conditions with few treatment options. The trade-off is that drugmakers must later confirm the drug’s clinical benefit through additional studies. In this case, the confirmatory study revealed a serious safety problem that outweighed the benefits.

What Experts Say About This Situation

Oncologists and patient advocates agree that this case highlights both the promise and the peril of cancer drug development. Accelerated approvals can give patients access to treatments years earlier than they might otherwise have them. But they also carry the risk that later studies will reveal unexpected harms.

“This is not a failure of the system,” says Dr. Mitchell. “It’s how the system is supposed to work. We identify a potential benefit, get the drug to patients who need it, and then carefully monitor for risks. When those risks become clear, we act.”

For patients with follicular lymphoma or epithelioid sarcoma, this news may feel like a setback. However, there are other treatment options available, including chemotherapy, immunotherapy, targeted therapies, and stem cell transplants for some cases. Patients should work closely with their healthcare team to find the best approach for their specific situation.

Practical Takeaways for Readers

If you or a loved one are currently taking or have taken tazemetostat, here are some important steps to consider:

• Do not stop your medication without talking to your doctor. Your healthcare team can help you weigh the risks and benefits based on your personal health history.
• Ask about monitoring. If you have taken tazemetostat, your doctor may recommend regular blood tests to check for signs of MDS, AML, or other blood disorders.
• Know the symptoms. Symptoms of MDS or AML can include unusual bruising or bleeding, frequent infections, fatigue, shortness of breath, and pale skin. Report any new symptoms to your doctor promptly.
• Discuss alternatives. If you are currently being treated for follicular lymphoma or epithelioid sarcoma, ask your oncologist about other treatment options that do not carry this specific risk.
• Stay informed. The FDA continues to monitor this situation. You can check the FDA’s website for updates on drug safety alerts.

Looking Ahead

The withdrawal of tazemetostat from the market is a sobering reminder that all medications—especially cancer drugs—carry risks. For patients who benefited from the drug during its brief time on the market, this news may be especially difficult. However, the scientific process worked as intended: a potential safety signal was identified, investigated, and acted upon to protect future patients.

Researchers will continue to study why some patients developed these secondary cancers and whether there are ways to predict or prevent them. In the meantime, patients and doctors must work together to make informed decisions about cancer treatment, balancing the fight against one disease against the risk of triggering another.

If you have questions about tazemetostat or your cancer treatment plan, speak with your healthcare provider. They can give you personalized advice based on your medical history and current condition.

Source: MedPage Today